Cytotoxic effects and aromatase inhibition by xenobiotic endocrine disrupters alone and in combination.
Xenobiotics may cause long-term adverse effects in humans, especially at the embryonic level, raising questions about their levels of exposure, combined effects, and crucial endpoints. We are interested in the possible interactions between xenobiotic endocrine disrupters, cellular viability and androgen metabolism. Accordingly, we tested aroclor 1254 (A1254), atrazine (AZ), o,p'-DDT, vinclozolin (VZ), p,p'-DDE, bisphenol A (BPA), chlordecone (CD), nonylphenol (NP), tributylin oxide (TBTO), and diethylstilbestrol (DES) for cellular toxicity against human embryonic 293 cells, and activity against cellular aromatase, but also on placental microsomes and on the purified equine enzyme. Cellular viability was affected in 24 h by all the xenobiotics with a threshold at 50 microM (except for TBTO and DES, 10 microM threshold), and aromatase was inhibited at non-toxic doses. In combination synergism was observed reducing the threshold values of toxicity to 4-10 microM, and aromatase activity by 50% in some cases. In placental microsomes the most active xenobiotics rapidly inhibited microsomal aromatase in a manner independent of NADPH metabolism. Prolonged exposures to low doses in cells generally amplified by 50 times aromatase inhibition. These xenobiotics may act by inhibition of the active site or by allosteric effects on the enzyme. Bioaccumulation is a feature of some xenobiotics, especially chlordecone, DDT and DDE, and low level chronic exposures can also affect cell signaling mechanisms. This new information about the mechanism of action of these xenobiotics will assist in improved molecular design with a view to providing safer compounds for use in the (human) environment.
Benachour
Nora
N
Laboratoire de Biochimie, EA2608, IBFA, Université de Caen, Esplanade de la Paix, 14032 Caen, France.
Moslemi
Safa
S
Sipahutar
Herbert
H
Seralini
Gilles-Eric
GE
D000735:Androstenedione / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D001141:Aromatase / Q000235:genetics / Q000378:metabolism*; D047072:Aromatase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D001559:Benzhydryl Compounds; D002384:Catalysis / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D007631:Chlordecone / Q000737:chemistry / Q000494:pharmacology; D004054:Diethylstilbestrol / Q000737:chemistry / Q000494:pharmacology; D052244:Endocrine Disruptors / Q000737:chemistry / Q000494:pharmacology*; D005260:Female; D006736:Horses; D006801:Humans; D008297:Male; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D015394:Molecular Structure; D010636:Phenols / Q000737:chemistry / Q000494:pharmacology; D011247:Pregnancy; D013737:Testis / Q000201:enzymology; D014162:Transfection; D014220:Trialkyltin Compounds / Q000737:chemistry / Q000494:pharmacology; D015262:Xenobiotics / Q000737:chemistry / Q000494:pharmacology*; D000098826:Bisphenol A Compounds
D000735:Androstenedione; D001141:Aromatase; D047072:Aromatase Inhibitors; D001559:Benzhydryl Compounds; D007631:Chlordecone; D004054:Diethylstilbestrol; D052244:Endocrine Disruptors; D010636:Phenols; D014220:Trialkyltin Compounds; D015262:Xenobiotics; C005961:bis(tri-n-butyltin)oxide; C025256:nonylphenol; C006780:bisphenol A; D000098826:Bisphenol A Compounds